Activation of protein kinase C by phorbol esters modulates α2β1 integrin on MCF-7 breast cancer cells

Experimental Cell Research

Volumn 248, Issue 1, 1999, Pages 260-271

  Rosfjord, Edward C ^a   Maemura, Michio ^a,b   Johnson, Michael D ^a   Torri, Jeffery A ^a   Akiyama, Steven K ^c   Woods Jr , Virgil L ^d   Dickson, Robert B ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GUNMA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adhesion; Breast carcinoma; Collagen; Integrin; PKC; Rho

Indexed keywords

BOTULINUM TOXIN; CALPHOSTIN C; COLLAGEN; GUANOSINE TRIPHOSPHATASE; INTEGRIN; LAMININ; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RHO FACTOR;

ARTICLE; BREAST CANCER; CELL ADHESION; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME;

CLOSTRIDIUM; MINK CELL FOCUS-FORMING VIRUS;

EID: 0033541446     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1998.4390     Document Type: Article

References (76)

1. Auerbach R. Patterns of tumor metastasis: Organ selectivity in the spread of cancer cells. Lab. Invest. 58:1988;361-364.
2. Blood C. H., Zetter B. R. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim. Biophys. Acta. 1032:1990;89-118.
3. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell. 64:1991;327-336.
4. McCormick B. A., Zetter B. R. Adhesive interactions in angiogenesis and metastasis. Pharmacol. Ther. 53:1992;239-260.
5. Albelda S. M. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab. Invest. 6:1993;4-17.
6. Maemura M., Dickson R. B. Are cellular adhesion molecules involved in the metastasis of breast cancer? Breast Cancer Res. Treat. 32:1994;239-260.
7. Akiyama S. K., Olden K., Yamada K. M. Fibronectin and integrins in invasion and metastasis. Cancer Metast. Rev. 14:1995;173-189.
8. Albini A., Aukerman S. L., Ogle R. C., Noonan D. M., Fridman R., Martin G. R., Fidler I. J. Thein vitro. Clin. Exp. Metast. 7:1989;437-451.
9. Dedhar S., Saulnier R. Alterations in integrin receptor expression on chemically transformed human cells: Specific enhancement of laminin and collagen receptor complexes. J. Cell Biol. 110:1990;481-489.
10. Dedhar S., Saulnier R., Nagle R., Overall C. M. Specific alterations in the expression of α3 β1 and α6β4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected byin vitro. Clin. Exp. Metast. 11:1993;391-400.
11. Danen E. H. J., van Muijen G. N. P., van de Wiel-van Kemenade E., Jansen K. F. J., Ruiter D. J., Figdor C. G. Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells. Int. J. Cancer. 54:1993;315-321.
12. Plantefaber L. C., Hynes R. O. Changes in integrin receptors on oncogenically transformed cells. Cell. 56:1989;281-290.
13. Peltonen J. P., Larjava H., Jaakola S., Gralnick H., Akiyama S. K., Yamada S. S., Yamada K. M., Uitto J. Localization of integrin receptors for fibronectin, collagen, and laminin in human skin variable expression in basal and squamous cell carcinomas. J. Clin. Invest. 84:1989;1916-1923.
14. Pignatelli M., Smith M. E. F., Bodmer W. F. Low expression of collagen receptors in moderate and poorly differentiated colorectal adenocarcinomas. Br. J. Cancer. 61:1990;636-638.
15. Korhonen M., Laitinen L., Ylanne J., Koukoulis G. K., Quaranta V., Juusela H., Gould V. E., Virtanen L. Integrin distribution in renal cell carcinomas of various grades of malignancy. Am. J. Pathol. 141:1992;1161-1171.
16. Jones J., Sugiyama M., Watt F. M., Speight P. M. Integrin expression in normal, hyperplastic, dysplastic, and malignant oral epithelium. J. Pathol. 169:1993;235-243.
17. Zutter M. M., Mazoujian G., Santoro S. A. Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am. J. Pathol. 137:1990;863-870.
18. Zutter M. M., Krigman H. R., Santoro S. A. Altered integrin expression in adenocarcinoma of the breast. Analysis byin situ. Am. J. Pathol. 142:1993;1439-1448.
19. 123. J. Pathol. 165:1991;25-32.
20. Pignatelli M., Cardillo M. R., Hanby A., Stamp G. W. Integrins and their accessory adhesion molecules in mammary carcinomas: Loss of polarization in poorly differentiated tumors. Hum. Pathol. 23:1992;1159-1166.
21. Mechtersheimer G., Munk M., Barth T., Koretz K., Moller P. Expression of βl integrins in non-neoplastic mammary epithelium, fibroadenoma and carcinoma of the breast. Virchow's Arch. A. 422:1993;203-210.
22. Jones J. L., Critchley D. R., Walker R. A. Alteration of stromal protein and integrin expression in breast - A marker of premalignant change? J. Pathol. 167:1992;399-406.
23. Gui G. P., Wells C. A., Browne P. D., Yeomans P., Jordan S., Puddefoot J. R., Vinson G. P., Carpenter R. Integrin expression in primary breast cancer and its relation to axillary nodal status. Surgery. 117:1995;102-108.
24. Rosfjord E. C., Dickson R. B. Role of integrins in the development and malignancy of the breast. Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics. 1999;Humana Press, Totowa.
25. Chan B. M. C., Matsuura N., Takada Y., Zetter B., Hemler M. E. In vitroin vivo. Science. 251:1991;1600-1602.
26. Goodnight J., Mischak H., Mushinski J. F. Selective involvement of protein kinase C isozymes in differentiation and neoplastic transformation. Adv. Cancer Res. 64:1994;159-209.
27. Liu J. P. Protein kinase C and its substrates. Mol. Cell Endocrinol. 116:1996;1-29.
28. Valette A., Gas N., Jozan S., Roubinet F., Dupont M. A., Bayard F. Influence of 12-O. Cancer Res. 47:1987;1615-1620.
29. Rovera G., O'Brien T. G., Diamond L. Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science. 204:1979;868-869.
30. O'Brian C. A., Vogel V. G., Singletary S. E., Ward N. E. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. 49:1989;3215-3217.
31. 2+. Cancer Res. 49:1989;2597-2602.
32. Johnson, M. D. Torri, J. T. Lippman, M. E. Dickson, R. B. 1994, Regulation of the invasiveness of the human breast cancer cell line MCF-7 by agents that act through protein kinase-C.
33. Ways D. K., Kukoly C. A., de Vente J., Hooker J. L., Bryant W. O., Posekany K. J., Fletcher D. J., Cook P. P., Parker P. J. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest. 95:1995;1906-1915.
34. Symons M. Rho family GTPases: The cytoskeleton and beyond. Trends Biol. Sci. 21:1996;178-181.
35. Takai Y., Sasaki T., Tanaka K., Nakanishi H. Rho as a regulator of the cytoskeleton. Trends Biochem. Sci. 20:1995;227-231.
36. Ridley A. J., Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 70:1992;369-399.
37. de Cremoux P., Gauville C., Closson V., Linares G., Calvo F., Tavitian A., Olofsson B. EGF modulation of the ras-related rhoB gene expression in human breast-cancer cell lines. Int. J. Cancer. 59:1994;408-415.
38. Aktories K., Rosener S., Blaschke U., Chhatwal G. S. Botulinum ADP-ribosyltransferase C3. Purification of the enzyme and characterization of the ADP-ribosylation reaction in platelet membranes. Eur. J. Biochem. 172:1988;445-450.
39. Sekine A., Fujiwara M., Narumiya S. Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. J. Biol. Chem. 264:1989;8602-8605.
40. Narumiya S., Morii N., Sekine A., Kozaki S. ADP-ribosylation of the rho/rac gene products by botulinum ADP-ribosyltransferase: Identity of the enzyme and effects on protein and cell functions. J. Physiol. 84:1990;267-272.
41. Nishiyama T., Sasaki T., Takaishi K., Kato M., Yaku H., Araki K., Matsuura Y., Takai Y. rac p21 is involved in insulin-induced membrane ruffling and rho p21 is involved in hepatocyte growth factor- and 12-O. Mol. Cell. Biol. 14:1994;2447-2456.
42. Takaishi K., Sasaki T., Kameyama T., Tsukita S., Tsukita S., Takai Y. Translocation of activated Rho from the cytoplasm to membrane ruffling area, cell-cell adhesion sites and cleavage furrows. Oncogene. 11:1995;39-48.
43. Akiyama S. K., Yamada S. S., Chen W.-T., Yamada K. M. Analysis of fibronectin receptor function with monoclonal antibodies: Roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. J. Cell Biol. 109:1989;863-875.
44. Pischel K. D., Hemler M. E., Huang C., Bluestein H. G., Woods V. L. Jr. Use of the monoclonal antibody 12F1 to characterize the differentiation antigen VLA-2. J. Immunol. 138:1987;226-233.
45. Coller B. S., Beer J. H., Scudder L. E., Steinberg M. H. Collagen-platelet interactions: Evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood. 74:1989;182-192.
46. Thompson E. W., Brunner N., Torri J., Johnson M. D., Boulay V., Wright A., Lippman M. E., Steeg P. S., Clarke R. The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin. Exp. Metast. 11:1993;15-26.
47. Dillon S. T., Feig L. A. Purification and assay of recombinant C3 transferase. Methods Enzymol. 256:1995;174-184.
48. Chomczynski P., Sacchi N. A rapid single step method for preparing RNA. Anal. Biochem. 162:1987;156-159.
49. Johnson M. D., Westley B. R., May F. E. B. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br. J. Cancer. 59:1989;727-738.
50. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 10:1982;7895-7903.
51. Laborda, J. 1991, 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO, Nucleic Acids Res. 19, 3998.
52. Saceda M., Knabbe C., Dickson R. B., Lippman M. E., Bronzert D., Lindsey R. K., Gottardis M. M., Martin M. B. Post-transcriptional destabilization of estrogen receptor mRNA in MCF-7 cells by 12-O. J. Biol. Chem. 266:1991;17809-17814.
53. Martin M. B., Garcia-Morales P., Stoica A., Solomon H. B., Pierce M., Katz D., Zhang S., Danielsen M., Saceda M. Effects of 12-O. J. Biol. Chem. 270:1995;25244-25251.
54. Fabbro D., Regazzi R., Costa S. D., Borner C., Eppenberger U. Protein kinase C desensitization by phorbol esters and its impact on growth of human breast cancer cells. Biochem. Biophys. Res. Commun. 135:1986;65-73.
55. Nishizuka Y. Studies and perspectives of protein kinase C. Science. 233:1986;305-312.
56. Kobayashi E., Nakano H., Morimoto M., Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:1989;548-553.
57. Gopalakrishna R., Barsky S. H. Tumor promoter-induced membrane-bound protein kinase C regulates hematogenous metastasis. Proc. Natl. Acad. Sci. USA. 85:1988;612-616.
58. Lane T. A., Lamkin G. E., Wancewicz E. V. Protein kinase C inhibitors block the enhanced expression of intercellular adhesion molecule-l, lipopolysaccharide and tumor necrosis factor. Biochem. Biophys. Res. Commun. 172:1990;1273-1281.
59. Farrar W. L., Anderson W. B. Interleukin-2 stimulates association of protein kinase C with plasma membrane. Nature. 315:1985;233-235.
60. Farrar W. L., Thomas T. P., Anderson W. B. Altered cytosol/membrane enzyme redistribution on interleukin-3 activation of protein kinase C. Nature. 315:1985;235-237.
61. Ostrowski J., Meier K. E., Stanton T. H., Smith L. L., Bomsztyk K. Interferon-γ and interleukin-l α induce transient translocation of protein kinase C activity to membranes in a B lymphoid cell line. Evidence for a protein kinase C-independent pathway in lymphokine-induced cytoplasmic alkalinization. J. Biol. Chem. 263:1988;13786-13790.
62. Deflippi P., Truffa G., Stefanuto G., Altruda F., Silengo L., Tarone G. Tumor necrosis factor α and interferon γ modulate the expression of the vitronectin receptor (integrin β3) in human endothelial cells. J. Biol. Chem. 266:1991;7638-7645.
63. Santala P., Heino J. Regulation of integrin-type cell adhesion receptors by cytokines. J. Biol. Chem. 266:1991;23505-23509.
64. Ezoe K., Horikoshi T. Tumor necrosis factor-α increased the integrin α2β1 expression and cell attachment to type I collagen in human dermal fibroblasts. Biochem. Biophys. Res. Commun. 192:1993;281-287.
65. Deflippi P., Silengo L., Tarone G. α6βl integrin (laminin receptor) is down-regulated by tumor necrosis factor α and interleukin-l β in human endothelial cells. J. Biol. Chem. 267:1992;18303-18307.
66. Danilov Y. N., Juliano R. L. Phorbol ester modulation of integrin-mediated cell adhesion: A postreceptor event. J. Cell Biol. 10:1989;1925-1933.
67. Symington B. E., Symington F. W., Rohrschneider L. R. Phorbol ester induces increased expression, altered glycosylation, and reduced adhesion of K562 erythroleukemia cell fibronectin receptors. J. Biol. Chem. 264:1989;13258-13266.
68. 1. Nature. 345:1990;250-253.
69. Gismondi A., Mainiero F., Morrone S., Palmieri G., Piccoli M., Frati L., Santoni A. Triggering through CD16 or phorbol esters enhances adhesion of NK cells to laminin via very late antigen 6. J. Exp. Med. 176:1992;1251-1257.
70. Coppolino M., Leung-Hagesteijn C., Dedhar S., Wilkins J. Inducible interaction of integrin alpha 2 beta 1 with calreticulin. Dependence on the activation state of the integrin. J. Biol. Chem. 270:1995;23132-23138.
71. Brown E., Hooper L., Ho T., Gresham H. Integrin-associated protein: A 50-kD plasma membrane antigen physically and functionally associated with integrins. J. Cell Biol. 111:1990;2785-2794.
72. Garcia L. J., Rosado J. A., Gonzalez A., Jensen R. T. Cholecystokinin-stimulated tyrosine phosphorylation of p125FAK and paxillin is mediated by phospholipase C-dependent and -independent mechanisms and requires the integrity of the actin cytoskeleton and participation of p21Rho. Biochem. J. 327:1997;461-472.
73. 2. J. Biol. Chem. 269:1994;463-469.
74. Lamph W. W., Wamsley P., Sassone-Corsi P., Verma I. M. Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature. 334:1988;629-631.
75. Imagawa M., Chiu R., Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: Protein kinase C and cAMP. Cell. 51:1987;251-260.
76. Burger S. R., Zutter M. M., Sturgill-Koszycki S., Santoro S. A. Induced cell surface expression of functional alpha 2 beta 1 integrin during megakaryocytic differentiation of K562 leukemic cells. Exp. Cell Res. 202:1992;28-35.